Needham analyst Ami Fadia downgraded Biogen (BIIB) to Hold from Buy.Don't Miss our Black Friday Offers:Discover the latest stocks recommended ...

TD Cowen analyst Phil Nadeau maintained a Buy rating on Biogen (BIIB – Research Report) today and set a price target of $275.00. The company’s shares closed yesterday at $164.89. According to ...

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...

Deep-pocketed investors have adopted a bearish approach towards Biogen (NASDAQ:BIIB), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga ...

Oct 30 (Reuters) - Biogen (BIIB.O), opens new tab raised its annual profit forecast on Wednesday, as new treatments and cost-cutting measures offset declining sales of its multiple sclerosis drugs.

Biogen (NASDAQ:BIIB) has agreed to pay Neomorph up to $1.45B plus royalties on any future products as part of a new collaboration deal for the discovery and development of molecular glue degraders ...

We think Biogen's neurology, immunology, and focus on rare diseases support a narrow moat. Biogen's strategy has its roots in the 2003 merger of Biogen (Avonex for treating multiple sclerosis ...

Shares of Biogen Inc. BIIB slid 1.48% to $165.79 Wednesday, on what proved to be an all-around favorable trading session for ...

Biogen raised its annual earnings guidance after reporting better-than-expected third-quarter sales and profit, driven by ongoing cost-cutting measures and the strong performance of its new ...

Biogen Inc.'s stock rose 1% Thursday, after Europe's pharmaceutical regulator issued a positive opinion on the Alzheimer's disease drug that the company developed with Japanese partner Eisai ...

The company's CEO warned on Wednesday that U.S. revenue for Leqembi, which it developed in partnership with Eisai Inc., “continues to be below the expectations of our collaboration.” ...

(Reuters) - Biogen raised its annual profit forecast on Wednesday, as new treatments and cost-cutting measures offset declining sales of its multiple sclerosis drugs. However, the drugmaker's ...